Loading…
Merck & Co., Inc. is projected to rise to $156.70 by 2027, a +27% move from its current price of $123.54. MRK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $121.55 | $123.60 | $125.68 | +0.05% |
| Jul 14 | $120.76 | $123.65 | $126.61 | +0.09% |
| Jul 15 | $120.17 | $123.71 | $127.35 | +0.14% |
| Jul 16 | $119.69 | $123.76 | $127.98 | +0.18% |
| Jul 17 | $119.27 | $123.82 | $128.54 | +0.23% |
| Jul 18 | $118.90 | $123.88 | $129.06 | +0.27% |
| Jul 19 | $118.57 | $123.93 | $129.54 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $118.57 | $123.93 | $129.54 | +0.32% |
| Week 2 | $116.78 | $124.33 | $132.36 | +0.64% |
| Week 3 | $115.52 | $124.72 | $134.66 | +0.96% |
| Week 4 | $114.52 | $125.12 | $136.70 | +1.28% |
| Week 5 | $113.69 | $125.52 | $138.58 | +1.60% |
| Week 6 | $112.98 | $125.92 | $140.34 | +1.93% |
| Week 7 | $112.36 | $126.32 | $142.02 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Merck & Co., Inc. operates as a healthcare company worldwide and offers human health pharmaceuticals under a broad portfolio of brands, including Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet. These products cover a range of human health areas and therapeutic categories.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
These descriptions reflect Merck’s broad scope in human and veterinary health through an extensive line of branded medicines, vaccines and animal health products described in the provided materials.
Merck & Co., Inc. (MRK) trades with a current price of $125.45 and sits at rank 42 with a market cap of $309.84B. The stock occupies a substantial position in the healthcare landscape, reflected by its sizable market capitalization.
The price outlook is illustrated by a year-by-year forecast that shows a path of rising averages from 2026 through 2050, with bullish sentiment intensifying in the later years. The forecasted averages begin at $125.45 in 2026 and rise to higher levels in subsequent years, peaking in the 2040s and 2050.
From a near-term technical standpoint, the stock currently faces a resistance at $125.45 and a support level at $111.38, with the 30-day range spanning from $111.93 to $140.61, suggesting a constructive setup within the present trading band. The 50-day and 200-day moving averages stand at $115.62 and $106.11 respectively, framing a bullish trajectory in the context of rising estimates over time.
A major floor 13.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 4.9% above — a clean break opens room to run.
A major ceiling 11.7% above — clearing it would confirm fresh momentum.
Key MRK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $126.05 | Sell | $125.47 | Sell |
| MA 10 | $127.17 | Sell | $125.35 | Sell |
| MA 20 | $122.60 | Buy | $123.57 | Sell |
| MA 50 | $118.22 | Buy | $120.21 | Buy |
| MA 100 | $118.21 | Buy | $116.72 | Buy |
| MA 200 | $108.35 | Buy | $110.48 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.97 | Neutral |
| Stoch RSI (14) | 20.50 | Neutral |
| CCI (20) | 12.89 | Neutral |
| Williams %R (14) | -42.76 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | 3.29 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 57.24 | Neutral |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | 5.06 | Buy |
| Ultimate (7,14,28) | 46.59 | Neutral |
| Momentum (10) | -1.91 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 124.90 | Sell |
| ADX (14) | 17.79 | Neutral |
| ATR (14) | 2.06 | Info |
The near-term technical picture is bullish, with RSI at 70 indicating strong momentum. The stock trades above its 50-day moving average of $115.62 and above the 200-day moving average of $106.11, signaling positive breadth.
Key support sits at $111.38 and resistance at $125.45, placing the current price near the upper end of the nearby trading range. The 30-day range runs from $111.93 up to $140.61, signaling potential upside within a measured window but also room for pullbacks if momentum shifts.
With an annualized volatility of 30%, the stock can experience meaningful swings, underscoring the importance of monitoring the evolving price action within the defined support and resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $106.45 | $123.54 | $165.48 | 0% | Neutral | |
| $128.33 | $156.70 | $200.04 | +27% | Bullish | |
| $148.74 | $185.02 | $242.59 | +50% | Bullish | |
| $166.37 | $210.15 | $281.40 | +70% | Bullish | |
| $170.76 | $218.61 | $298.01 | +77% | Bullish | |
| $181.34 | $234.99 | $325.39 | +90% | Bullish | |
| $191.32 | $250.72 | $352.11 | +103% | Bullish | |
| $207.31 | $274.54 | $390.55 | +122% | Bullish | |
| $253.26 | $338.72 | $487.62 | +174% | Bullish | |
| $267.58 | $361.27 | $525.86 | +192% | Bullish | |
| $363.92 | $512.46 | $781.70 | +315% | Bullish | |
| $639.69 | $966.09 | $1,579.65 | +682% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $106.45 | $123.54 | $149.87 | +0.00% |
| August 2026 | $110.03 | $128.81 | $154.08 | +4.27% |
| September 2026 | $109.46 | $128.76 | $155.21 | -0.04% |
| October 2026 | $111.97 | $132.24 | $160.46 | +2.70% |
| November 2026 | $114.78 | $136.04 | $165.97 | +2.87% |
| December 2026 | $113.49 | $134.95 | $165.48 | -0.80% |
Click any year to see its month-by-month MRK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MRK is projected to trade between $106.45 and $165.48, averaging $123.54 — a potential gain of 0% from today's $123.54. A consolidation phase looks the most probable path here.
Merck & Co., Inc.'s 2027 outlook centres on $156.70, within a $128.33 to $200.04 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2028, MRK could reach as high as $242.59, with a base case around $185.02 and support toward $148.74 — roughly +50% from $123.54. Buyers look set to stay in control over this stretch.
Expect MRK to range from $166.37 to $281.40 through 2029. The $210.15 average target implies a +70% move from current prices. That is up +14% on the projected 2028 average. Momentum favours further upside here.
The MRK price prediction for 2030 points to an average of $218.61 (low $170.76, high $298.01) — a potential gain of +77% on today's $123.54. Buyers look set to stay in control over this stretch.
In 2031, MRK is projected to trade between $181.34 and $325.39, averaging $234.99 — a potential gain of +90% from today's $123.54. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Merck & Co., Inc.'s 2032 outlook centres on $250.72, within a $191.32 to $352.11 range. That is up +7% on the projected 2031 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MRK could reach as high as $390.55, with a base case around $274.54 and support toward $207.31 — roughly +122% from $123.54. Momentum favours further upside here.
Expect MRK to range from $253.26 to $487.62 through 2034. The $338.72 average target implies a +174% move from current prices. That is up +23% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MRK price prediction for 2035 points to an average of $361.27 (low $267.58, high $525.86) — a potential gain of +192% on today's $123.54. Momentum favours further upside here.
In 2040, MRK is projected to trade between $363.92 and $781.70, averaging $512.46 — a potential gain of +315% from today's $123.54. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Merck & Co., Inc.'s 2050 outlook centres on $966.09, within a $639.69 to $1,579.65 range. That is up +89% on the projected 2040 average. That marks a +682% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MRK today (≈ 8.094544 MRK) could be worth
$7,820.03
+$6,820.03 (+682%) by 2050 · US Dollar
Based on the average projected MRK price of $966.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRKwould be worth at today's price.
$1,000 invested in MRK on Jul 10, 2025 (≈ 11.901929 MRK) would be worth
$1,470.36
+$470.36 (+47.0%) today · 1.47× · US Dollar
Based on a MRK entry price of $84.02 vs. today's $123.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $129.56 | $953.54 | -4.6% |
| 1 month ago | $119.09 | $1,037.37 | +3.7% |
| 3 months ago | $121.42 | $1,017.46 | +1.7% |
| 6 months ago | $109.19 | $1,131.42 | +13.1% |
| 1 year ago | $84.02 | $1,470.36 | +47.0% |
| All time (5.0y) ago | $77.61 | $1,591.81 | +59.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRK forecast.
Our base-case forecast reaches $250.00 around 2032.
Implied market cap at $250.00: $617.46B
The multi-year forecast shows a sustained bullish trajectory with rising averages and meaningful upside potential into the next decades. In 2026 the avg price is projected at $125.45 with a min of $106.45 and a max of $167.21, yielding a neutral sentiment for that year. From 2027 onward, the outlook becomes increasingly bullish, with the avg climbing to $162.31 (ROI 29.4%) and then $189.45 (ROI 51%) in 2028 and $213.63 (ROI 70.3%) in 2029.
By 2030 the avg is $225.85 (ROI 80%), and the bullish trend continues through 2031 ($238.98, ROI 90.5%), 2032 ($255.96, ROI 104%), and 2033 ($286.82, ROI 128.6%). The path remains strong into 2034 ($346.70, ROI 176.4%) and 2035 ($368.05, ROI 193.4%). The forecast projects substantial upside by 2040, with an avg of $530.01 (ROI 322.5%), and by 2050 an avg of $982.42 (ROI 683.1%).
These figures reflect a bullish sentiment across the long horizon, though they are estimates and not guarantees. Potential drivers and risks include general market conditions and sector dynamics, which could influence actual results versus forecasts.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $225.85 with a min of $176.32 and a max of $308.08, and a bullish sentiment, with an ROI of 80%.
The forecast progresses from neutral in 2026 to bullish from 2027 onward, with rising averages and positive ROIs (e.g., 29.4% in 2027, 80% in 2030, and higher in later years), though these are estimates and not guarantees.
Yes—according to the forecast, the max price in 2050 is $1,606.76, with an avg of $982.42 and a bull market sentiment through 2050.
The current price is $125.45 and the market cap is $309.84B, with a market rank of 42.
RSI14 is 70 with a bullish sentiment. The 50-day SMA is $115.62 and the 200-day SMA is $106.11. Near-term support is at $111.38 and resistance at $125.45, with a 30-day price range of $111.93 to $140.61.
Merck & Co., Inc. Community Discussion
0Share your Merck & Co., Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.